Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-Selectin Nasal Spray for Secondary Stroke Prevention
NCT00012454Phase 2Terminated
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Mar 2001
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of e-selectin in stroke and Transient Ischemic Attack (TIA) (4 arms), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Induction of mucosal tolerance to E-selectin. Started Mar 2001; status: terminated.
02
Drugs
e-selectin
03
Conditions
strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT00012454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012454.